CM
NASDAQ · CMND
Clearmind Medicine Inc.
Healthcare · Biotechnology
$0.86
Down-$0.05 (-6.05%)
Updated Sep 16, 2026, 2:03 PM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 387.88K
- P/E ratio
- -0.07
- Dividend yield
- 0.00%
- 52-week range
- $0.52 – $6.03
- Volume
- 168.73K
- Avg. volume
- 13.42M
Price performance
CMND price history
1M range · 20 trading sessions · Daily adjusted prices
CMND closed at $0.86 after 20 trading sessions, down 55.90% for the selected period.
- Last close
- $0.86
- Period change
- -55.90%
- Period low
- $0.86
- Period high
- $1.96
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $0.918 | $0.9329 | $0.8333 | $0.8643 | 168.73K |
| Sep 14, 2026 | $0.94 | $0.9698 | $0.9173 | $0.944 | 168.85K |
| Sep 11, 2026 | $0.9998 | $1.06 | $0.95 | $0.9667 | 288.31K |
| Sep 10, 2026 | $1.00 | $1.045 | $0.9803 | $0.9816 | 102.84K |
| Sep 9, 2026 | $1.07 | $1.11 | $1.00 | $1.06 | 336.83K |
| Sep 8, 2026 | $1.15 | $1.15 | $0.9199 | $1.03 | 3.12M |
| Sep 4, 2026 | $1.495 | $1.555 | $1.16 | $1.16 | 15.51M |
| Sep 3, 2026 | $1.81 | $1.84 | $1.70 | $1.70 | 60.08K |
| Sep 2, 2026 | $1.85 | $1.8699 | $1.79 | $1.85 | 47.22K |
| Sep 1, 2026 | $1.93 | $1.93 | $1.76 | $1.83 | 221.47K |
| Aug 31, 2026 | $1.82 | $2.10 | $1.81 | $1.94 | 718.96K |
| Aug 28, 2026 | $1.82 | $1.8399 | $1.73 | $1.76 | 24.79K |
| Aug 27, 2026 | $1.85 | $1.85 | $1.75 | $1.81 | 65.47K |
| Aug 26, 2026 | $1.68 | $1.74 | $1.66 | $1.72 | 37.89K |
| Aug 25, 2026 | $1.6897 | $1.75 | $1.65 | $1.71 | 42.81K |
| Aug 24, 2026 | $1.75 | $1.75 | $1.61 | $1.68 | 97.17K |
| Aug 21, 2026 | $1.74 | $1.835 | $1.74 | $1.74 | 47.14K |
| Aug 20, 2026 | $1.93 | $1.93 | $1.70 | $1.73 | 109.39K |
| Aug 19, 2026 | $1.96 | $1.96 | $1.88 | $1.91 | 63.44K |
| Aug 18, 2026 | $1.88 | $2.31 | $1.84 | $1.96 | 835.58K |
Latest CMND news
The latest Smart Investors Daily articles mentioning CMND.
Stock researchResearch & News · Competitors
Loading stock research…
